Short Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Drops By 53.9%

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totaling 6,135 shares, a decrease of 53.9% from the April 30th total of 13,319 shares. Based on an average daily trading volume, of 56,976 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genenta Science in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Genenta Science presently has an average rating of “Sell”.

Institutional Trading of Genenta Science

Hedge funds have recently made changes to their positions in the company. Ghisallo Capital Management LLC acquired a new stake in shares of Genenta Science in the 4th quarter worth $482,000. SmartHarvest Portfolios LLC lifted its stake in shares of Genenta Science by 656.1% in the 1st quarter. SmartHarvest Portfolios LLC now owns 134,447 shares of the company’s stock worth $90,000 after acquiring an additional 116,666 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Genenta Science in the 3rd quarter worth $41,000. Norges Bank acquired a new stake in shares of Genenta Science in the 4th quarter worth $337,000. Finally, Weiss Asset Management LP acquired a new stake in shares of Genenta Science in the 4th quarter worth $480,000. Institutional investors and hedge funds own 15.13% of the company’s stock.

Genenta Science Price Performance

NASDAQ:GNTA traded up $0.14 during trading hours on Friday, reaching $1.03. 819,079 shares of the company’s stock were exchanged, compared to its average volume of 507,535. The company has a 50-day moving average of $0.69 and a 200 day moving average of $1.12. The company has a quick ratio of 14.16, a current ratio of 14.16 and a debt-to-equity ratio of 0.35. Genenta Science has a 1-year low of $0.55 and a 1-year high of $10.00.

Genenta Science (NASDAQ:GNTA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.28.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.